Feasibility of Opportunistic Salpingectomy at the Time of Vaginal Hysterectomy for Benign Pathology


Original post, click here

This study has been completed.

Sponsor:

Information provided by (Responsible Party):

Hospices Civils de Lyon

ClinicalTrials.gov Identifier:

NCT03187327

First received: June 13, 2017

Last updated: June 13, 2017

Last verified: May 2017

In this prospective study, patients who underwent vaginal hysterectomy with salpingectomy or salpingo-oophorectomy were included. The objective of this study is to assess the feasibility of prophylactic salpingectomy during vaginal hysterectomy for benign pathology and the prevalence of occult tubal lesions. The hypothesis is that prophylactic salpingectomy during vaginal hysterectomy for benign pathology present a low failure rate and it makes it possible to avoid the appearance of a certain number of ovarian cancers. The prevalence of bilateral salpingectomy with or without ovariectomy and the prevalence of histopathological and immunohistochemical (p53 expression) abnormalities were evaluated.

Salpingectomy
Hysterectomy

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Feasibility of Opportunistic Salpingectomy at the Time of Vaginal Hysterectomy for Benign Pathology and Evaluation of Occult Tubal Lesions Prevalence: Preliminary Study

Primary Outcome Measures:

Enrollment: 69
Actual Study Start Date: September 2013
Study Completion Date: January 2015
Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample

Patients who underwent vaginal hysterectomy with salpingectomy or salpingo-oophorectomy

Inclusion Criteria:

  • patients who underwent vaginal hysterectomy for benign pathology with salpingectomy or salpingo-oophorectomy

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT03187327

Hôpital Femme Mère Enfant
Bron, France

Hospices Civils de Lyon

Principal Investigator: Gautier CHENE Hospices Civils de Lyon

Responsible Party: Hospices Civils de Lyon
ClinicalTrials.gov Identifier: NCT03187327     History of Changes
Other Study ID Numbers: 69HCL17_0352
Study First Received: June 13, 2017
Last Updated: June 13, 2017
Individual Participant Data  
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Hospices Civils de Lyon:

prophylactic salpingectomy
vaginal hysterectomy
p53 expression
ovarian cancers

ClinicalTrials.gov processed this record on June 14, 2017